The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11in the US market following approval.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...